Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA. 5 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Selecta Biosciences in the last twelve months.
© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Insiders have purchased a total of 4,207,282 SELB shares in the last 24 months for a total of $12,524,992.26 bought.
Selecta Biosciences, Inc. (SELB) Q2 Earnings and Revenues Surpass Estimates
Insiders that own company stock include Carrie Smith Cox, Carsten Brunn, Kevin Tan, Lloyd P Johnston, Nishan M Desilva, Peter G Traber, Timothy A Springer, Timothy C Barabe and Timothy C Barabe. Want to know when executives and insiders are buying or selling Selecta Biosciences stock? Sign up for InsiderTrades.com’s daily newsletter to get the latest insider transactions delivered to your inbox daily. While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. According to 5 analysts, the average rating for SELB stock is “Strong Buy.” The 12-month stock price forecast is $6.0, which is an increase of 453.00% from the latest price.
Selecta Biosciences Shares Rise Premarket on Positive Gout Studies >SELB – MarketWatch
Selecta Biosciences Shares Rise Premarket on Positive Gout Studies >SELB.
Posted: Tue, 21 Mar 2023 07:00:00 GMT [source]
You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
MarketWatch
(SELB) raised $64 million in an initial public offering on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.
- Zacks Ranks stocks can, and often do, change throughout the month.
- – Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) (Sobi); DISSOLVE I & II studies remain on track for joint topline …
- 30.50% of Selecta Biosciences stock is owned by insiders.
- Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat’s FREE daily newsletter.
Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat’s FREE daily newsletter.
Analyst Ratings
View analysts price targets for SELB or view top-rated stocks among Wall Street analysts. Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -200% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the … Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 25% and 32.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto… Selecta Biosciences’ stock is owned by a number of retail and institutional investors.
Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. 5 Wall Street analysts have issued 1 year price targets for Selecta Biosciences’ stock. Their SELB share price forecasts range from $4.00 to $9.00. On average, they expect the company’s stock price to reach $6.00 in the next year. This suggests a possible upside of 453.0% from the stock’s current price.
Selecta Biosciences, Inc. (SELB) Reports Q4 Loss, Tops Revenue Estimates
The consensus among Wall Street equities research analysts is that investors should “buy” SELB shares. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year. These returns cover a period from January 1, 1988 through April 3, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.
Selecta Biosciences, Inc. (SELB) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.08. One share of SELB stock can currently be purchased for approximately $1.09. The list of insiders at Selecta Biosciences includes Carrie Smith Cox, Carsten Brunn, Kevin Tan, Lloyd P Johnston, Nishan M Desilva, Peter G Traber, Timothy A Springer, Timothy C Barabe. – Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) (Sobi); DISSOLVE I & II studies remain on track for joint topline …
A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month.
Insiders have sold a total of 103,000 Selecta Biosciences shares in the last 24 months for a total of $261,732.10 sold. 30.50% of Selecta Biosciences stock is owned https://business-oppurtunities.com/your-business/ by insiders. Selecta Biosciences, Inc. (SELB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company’s earnings prospects.
- Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -200% and 37.24%, respectively, for the quarter ended September 2022.
- Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy.
- This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.
- 5 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Selecta Biosciences in the last twelve months.
- While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities.